ShanghaiSoho-YimingPharmaceuticalsCo.,Ltd.——China'sleadingGMPpeptideAPIenterprise,Shanghaihigh-techenterprise
Soho-YimingPharmaceuticalsCo.,Ltd(awhollyownedsubsidiarybyAnkebio)wasfoundedin2001.Itisahigh-techenterprisefocusedonresearch,development,productionandsalesofdifferentkindsGMPpeptideAPI.
Ourcompanyownsthefirst-classfacilitiesofexperimentandproduction,suchasautomaticpeptidesynthesissystem,separationandpurificationsystem,freezedryingsystemandotherinstruments.Byintroducing,digesting,absorbingthemostadvancedpeptidesynthesistechnologyintheworld,wehaveestablishedaleadinghigh-techplatformforactivesmallmoleculepeptidedrugsinChina.Ourcompanyalsoindependentlyinventasolidphasetechnologicalprocesswhichissuitableforindustrializedproduction.Weprovidehighqualitypeptideproductsforinjectionenterpriseintheworld.Sofar,therearemorethan60kindsofpeptideAPIhavegonepublicandintheclinicalstage.TherangeandoutputofproductsisalwaysintheleadingpositioninChina.Meanwhile,Soho-Yimingprovideshighqualityproducts,purificationservice,synthesisreagentandtechnologyconsultingofpeptideAPI.
Thevisionofourcompanyisbyintroducinganddigestingtheadvancedpeptideproductiontechnology,relyingonthecutting-edgebiotechnologytocontinuouslyimprovenotonlytechnologylevelbutalsoscientificstrength.Soho-Yiminghascreatedafaithful,positive,innovativeandcooperativecorporationculture.Strivingtoimproveproductsqualityandprovideclientswithhighqualityproducts.Wehavebeencommittedtoforgeourcompanyintothelargest,mostinfluentialpeptidepharmaceuticalsenterpriseinChina.
Wehavebeenawardedasnationalhigh-techenterprisesince2007,itisalsoknownas“tech-giant”inPutuodistrict.TheSomatostain,OctreotideAcetate,SalmonCalcitonin,Thymopentin,Leuprorelin,OxytocinandThymalfasinhavewontheShanghaihigh-techachievementstransformationprize.SomatostainownsthehonorofShanghaikeyproduct,atthesametime,SomatostainandThymalfasinwasalsolistedasinnovationfundsprojectbyMOST(MinistryofScienceandTechnology).OctreotideAcetatewasselectedintothe“NationalTorchProgram”.Soho-Yiminghasbeentakenasthetop50pharmaceuticalsenterprisewithitshugedevelopmentpotential.
Soho-Yimingpaysgreatimportancetotheprotectionofintellectualproperty.Ourcompanyhasappliedformorethan30kindinventionpatentincludingOxytocin,OctreotideAcetate,Leuprorelin,Somatostain,etc.WhatisworthtobementionedisthatOctreotideAcetatewonthefirstprizeofShanghai18thexcellentinvention.Inaddition,SomatostainandOxytocinwasawardedthesecondprizeof19thand20thexcellentinventioninShanghai.
Mr.zhou,Soho-Yiming’sfounder,isthedirectorofChinaBiochemicalPharmaceuticalsIndustryAssociation,technicalexpertoftheMOST,memberofShanghaiexpertdatabase.Healsoownedthetop20excellentinventionhonorinthepast20years.
Ourcompanyhasremovedtoabrandnewlarge-scaleGMPpeptideproductionbaseinQingpudistrict,Shanghaiin2017.Sincethen,theenvironment,capacityandhardwarefacilitieshavebeenupgradecomprehensively.AccordingtocurrentGMPrequirements,wehaverealizedthestrictcontroltoourproductsqualitywithcomprehensiveGMPmanagementandpassedtheFDAon-siteinspectionwithnodeficiencyin2017.Tillnow,Soho-YiminghasbecometheuniquepeptideAPIsupplierinChinawhohas6GMPapproval.IncludingThymalfasin,Thymopentin,Somatostain,SalmonCalcitonin,OctreotideAcetateandAtosibanAcetate.Besides,wealsoactivelypromoteveterinarymarket,theGonadorelinandLHRH-A3alsogottheanimaldrugsGMPcertificateissuedbyShanghaiAgricultureandRuralCommitteein2019.WiththecontinuoushardworkingofallstaffinSoho-Yiming,ourcompanyalsoobtainedCEPcertificatesforOxytocinandSalmonCalcitoninin2017,whichisveryhelpfulforustosuccessfullyenterEUmarket.
Fornow,ourcompanyisabletoachievebatchproductionof6kg,thesalesofvariouskindhighpurity(above99%)peptideAPIcouldbe300kgforeveryyearandannualrevenuenearly100million.Meanwhile,Soho-Yiming’sproductioncapacityisabout500kgandmarketsharehasalwaysrankedfirstinChinaforyears.ShanghaiSoho-YimingPharmaceuticalsCo.,Ltd.isthemainstayofChinesepeptideAPIindustryandwinslotsofhonorinpeptidefields.Soho-Yimingwillstillmoveforwardandmakecontributionforworldpeptidepharmaceuticalsbusinessinthefuture.